Allergan Plc (AGN)

164.04
0.43 0.26
NYSE : Health Technology
Prev Close 164.47
Open 164.40
Day Low/High 162.90 / 165.75
52 Wk Low/High 156.00 / 256.80
Volume 2.65M
Avg Volume 2.99M
Exchange NYSE
Shares Outstanding 332.58M
Market Cap 54.03B
EPS -13.20
P/E Ratio N/A
Div & Yield 2.88 (1.68%)

Latest News

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

The chief commercial officer of the Dublin drugmaker describes the long-term outlook for the medical aesthetics business as 'exceptional.'

A Look Around Today's Market

As quick as last week's selloff occurred, this rebound higher has been just as fast, and we would not be surprised to see the market retest at some point.

Aegon Supervisory Board Member Dirk Verbeek To Step Down At Next AGM

Aegon Supervisory Board Member Dirk Verbeek To Step Down At Next AGM

Aegon announces that Dirk P.M.

Aegon Concludes 2017 With Solid Fourth Quarter Results

Aegon Concludes 2017 With Solid Fourth Quarter Results

Net income more than doubles driven by US tax reform Underlying earnings decrease by 5% to EUR 525 million as a result of a weakening of the US dollar; expense savings and higher fee revenue...

Trimming Allergan

We are reducing our Allergan holdings on today's strong move.

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

In this tape, weakness may just be a sign of rest and better times to come.

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

As lawsuits tied to the opioid crisis keep piling up, Purdue Pharma is discontinuing direct sales calls to doctors. Will other opioid makers follow suit?

Jim's Daily Rundown

Jim discusses our First Data Corp exit, his interview with Broadcom's CEO, Nvidia, and his Real Money article from earlier today.

Weekly Roundup

Markets extend losses in volatile week.

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.

Teva Nailed With S&P Downgrade

Teva Nailed With S&P Downgrade

The downgrade to BB from BBB- comes as the drugmaker continues to face challenges such as a competitive generic drug market in the U.S.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Allergan Becomes #152 Most Shorted S&P 500 Component, Replacing Cardinal Health

Allergan Becomes #152 Most Shorted S&P 500 Component, Replacing Cardinal Health

The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Jim's Daily Rundown

Jim discusses this morning's buy of Nordstrom, Allergan's earnings from yesterday and his view on a few upcoming earning reports.

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

Centene and Laboratory Corp. of America were among the healthcare stocks in the green on Tuesday, Feb. 6, amid a volatile trading day in the stock market.

Allergan Beats Expectations, but Shares Still Pressured

The overhang of the trough earnings year and how loss of exclusivity on drugs will play out has AGN stuck in a holding pattern.

Allergan CEO: We Are Staying in Ireland

Allergan CEO: We Are Staying in Ireland

On an earnings call, Allergan's top executive rejected the possibility of moving back to the U.S. on the heels of the new tax law.

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

Maybe inverse and/or leveraged positions are perverse in nature.

The Dow's Wild Ride - 5 Things You Must Know Before the Market Opens Tuesday

The Dow's Wild Ride - 5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures are swinging wildly in and out of positive territory on Tuesday, and European stocks suffer steep declines, as investors try to make sense of a market rout that has spread globally.

Allergan Announces Positive Top Line Phase 3 Results For Ubrogepant - An Oral CGRP Receptor Antagonist For The Acute Treatment Of Migraine

Allergan Announces Positive Top Line Phase 3 Results For Ubrogepant - An Oral CGRP Receptor Antagonist For The Acute Treatment Of Migraine

- Topline results from ACHIEVE I (UBR-MD-01) study demonstrate efficacy, safety and tolerability -

Cramer vs. Chaikin: You Can't Trade Allergan

Cramer vs. Chaikin: You Can't Trade Allergan

TheStreet's Jim Cramer and Marc Chaikin, of Chaikin Analytics, spent an hour together at our offices talking all things markets. Listen to the whole conversation below. In the except above, they discuss Allergan and why you can't trade it.

Allergan's Pipeline Matters More Than Its Earnings Do: RBC

Allergan's Pipeline Matters More Than Its Earnings Do: RBC

Positive pipeline updates are the 'biggest upside driver' for Allergan shares ahead of Tuesday earnings.

Last Week's Portfolio Changes

We raised three price targets and downgraded three ratings during a busy earnings week.

Weekly Roundup

Big market selloff

FDA Approves AVYCAZ® (ceftazidime And Avibactam) For The Treatment Of Patients With Hospital-Acquired Bacterial Pneumonia And Ventilator-Associated Bacterial Pneumonia

FDA Approves AVYCAZ® (ceftazidime And Avibactam) For The Treatment Of Patients With Hospital-Acquired Bacterial Pneumonia And Ventilator-Associated Bacterial Pneumonia

-- First Gram-Negative Antibiotic Approved in the U.S. to Treat HABP/VABP in Over 15 Years --

TheStreet Quant Rating: D+ (Sell)